Infliximab, adalimumab, etanercept, certolizumab, and golimumab have recognized efficacy in refractory PG and are associated with IBD [26], according to a semi-systematic review published by Ben Abdallah et al. After analyzing 222 articles that included 356 patients with PG treated with TNF-α inhibitors, an 87% response rate and 67% complete remission were described, without finding significant differences between different drugs in terms of effectiveness [23]. This evidence concerns the gene TNF and inflammatory bowel disease.